<DOC>
	<DOCNO>NCT00997542</DOCNO>
	<brief_summary>The purpose study discover whether inhibition xanthine oxidase allopurinol lead reduction production oxygen free radical patient CHF thereby improve characteristic oxydative metabolism , peripheral blood flow , immune function functional status .</brief_summary>
	<brief_title>Allopurinol Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>The patient male least 21 year age . The patient clinical evidence heart failure : ) reduce ejection fraction ( ≤40 % ) cardiomegaly CXR leave ventricular impairment echocardiography ( LVEDD ≥60mm ) , b ) stable clinical condition medication least 1 month prior study . No history unstable angina , myocardial infarction stroke within 3 month prior study . The patient receive full conventional medical therapy heart failure ( ACE inhibitor angiotensin II blocker , diuretic etc. ) . The patient willing capable complying requirement protocol . The patient provide write informed consent . The patient lifethreatening disease , heart failure ( include patient know , suspect , myocarditis automatic implantable cardioverter/defibrillators ) . The patient active malignancy type , history malignancy ( Patients history basal cell carcinoma surgically remove acceptable ) . Patients history malignancy surgically remove evidence recurrence least five year prior study enrolment also acceptable . The patient heart transplant . The patient severe renal disease ( SCreatinine &gt; 300 μmol/l ) , severe liver disease ( ASAT ALAT &gt; 3 time upper limit normal range ) , rheumatoid arthritis , complain gout . The patient receive allopurinol therapy previously know suffer gout ( acutely chronically ) . The patient exercise capacity &gt; 20 ml/kg/min ( treadmill , Bruce protocol ) functional NYHA class I .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>